Loading
Permanent scarring of the liver after years of damage from hepatitis B or C, alcohol or fatty liver disease. It is the soil in which most liver cancers grow, and its severity limits which cancer treatments a patient can withstand.
Around 80-90% of hepatocellular carcinomas arise in cirrhotic livers, at roughly 2-4% per year, which is why patients with cirrhosis are offered six-monthly ultrasound and AFP surveillance. Hepatitis B vaccination and antiviral therapy, hepatitis C cure with direct-acting antivirals and, prospectively, GLP-1 agonists for metabolic liver disease are the main preventive levers. Cirrhosis also complicates treatment: it causes portal hypertension, low platelets and impaired drug clearance, and is graded by Child-Pugh and ALBI for treatment eligibility.
Hepatocellular carcinoma grows in a cirrhotic liver and spreads first inside it and into the portal vein, so staging depends on liver function and vascular invasion as much as on size.
Same organ: Early hepatocellular carcinoma (BCLC 0 and A), Intermediate hepatocellular carcinoma (BCLC B), Advanced hepatocellular carcinoma (BCLC C), Hepatoblastoma
Showing the organ this term concerns: Hepatocellular carcinoma.
Shares BCLC staging, Hepatocellular carcinoma.
Shares Portal vein tumour thrombus (macrovascular invasion), Hepatocellular carcinoma.
Shares BCLC staging, Hepatocellular carcinoma.
Shares BCLC staging, Hepatocellular carcinoma.
Shares Child-Pugh score, Hepatocellular carcinoma.
Shares Portal vein tumour thrombus (macrovascular invasion), BCLC staging, Hepatocellular carcinoma.
Shares LI-RADS (Liver Imaging Reporting and Data System), Hepatocellular carcinoma.
Shares BCLC staging, Hepatocellular carcinoma.